Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis
Epistemonikos ID: c850abf38e632909727ba98a282223d6e065881c
First added on: Mar 23, 2020